SlideShare ist ein Scribd-Unternehmen logo
1 von 12
Downloaden Sie, um offline zu lesen
Conference Call – 3Q06 Results
Profarma’s Overview
   Pharmaceutical Manufacturers                                       Drug Retailers




                                                                                           BA
                                                                               GO
                                                                                     DF
                                                                                       MG ES
                                                                                S
                                                                                           RJ
                                                                              PRP
                                                                                SC

                                  • 8 Distribution Centers                           Distribution Centers

                                  • > 9,100 Orders Daily
                                  • Additional Value Added Services
      # 120 manufacturers                                                      # 23,800
      served by Profarma                                                 Points-of-Sale
                                                                  Supplied by Profarma

     Profarma is the fastest growing wholesale distributor of pharmaceutical
                       and personal care products in Brazil
Investiment thesis
                        Positive Sector
                          Dynamics
             Strong                         Multiple
           Financial                        Growth
          Performance                     Opportunities


          Experienced
          Management                       Key Player
             Team
                        Proven Track
                           Record
Highlights – 3Q05 vs. 3Q06
   - Profarma’s IPO inaugurates company’s new moment
       - Trade of 17.8 million common shares at R$ 22.50
       - Gross funding of R$ 401.0 million
       - Primary Offer of R$ 310.5 million


   - 3Q06 Gross Revenues of R$529 million, 16.4% growth over 3Q05


   - Net Income totaled R$ 4.2 million, 20.8% more than in the 3Q05.


   - Adjusted EBITDA reached R$ 19.1 million, 11.4% up year-on-year.
Gross Revenues Growth                                                R$ Million




                                      12.9%                  16.4%
          25.1%
                                               1,439                    529
                     1,725
                             1,274
                                               125     455              47
            1,443     131
                              97               253     35               90
             101      307
  1,102                       229              76      80               31
             252      103
    59       60               75                       28
   185
    34
                     1,184    873              985                      361
             1,030                                     312
   823



  2003       2004    2005    9M2005           9M2006   3Q05             3Q06
Net Income                                                                  R$ Million



                         33.6%                                70.5%


                         12.0%                                20.8%

                                          10.6
                                                                      5.9
                                          8.9
         8.0
                                                                      4.2
                                                       3.5




      9M2005                            9M2006         3Q05           3Q06
   Net Income
   Net Income, excluding expenses related to the IPO
Adjusted EBITDA
                             Adjusted EBITDA (R$ Million)

              31.4%
                                     13.8%                         11.4%

                      61.6
       35.7   47.1            42.8            48.7
                                                            17.1           19.1
       2003    2004   2005    9M2005         9M2006         3Q05           3Q06




                               % of Net Revenues


       3.6%   3.7%    4.1%                                  4.3%           4.1%
                              3.8%            3.8%




       2003    2004   2005    9M2005         9M2006         3Q05           3Q06
% of Net Revenues

Operating Expenses
  General & Administratives
                           2.46%                 2.23%              2.14%                2.16%              1.94%
                                         2.14%
       2.34%
                  2.02%                          9M2005            9M2006                3Q05               3Q06
  Comercial & Marketing                                               General and Administratives
                                        2.34%
      2.22%      2.21%       2.24%                2.51%                                   2.83%
                                                                    2.34%                                    2.50%

  Logistics & Distribution                        2.93%             2.44%                 2.49%              2.40%

        2.92%    2.71%        2.88%
                                                 9M2005            9M2006                3Q05                3Q06
                                         2.44%            Comercial and Marketing    Logistics and Distribution
  Operating Expenses
       7.43%    6.45%        7.11%               7.56%               6.27%               7.01%               6.38%
                                         6.27%
                                                 9M2005             9M2006               3Q05                3Q06
     2003       2004      2005        9M2006                        Operating Expenses
Market Follow-up (from October 25 through November 10)
     127                                                                                                                       126.7
                                                                                                                                                                     126.2

     124                                                                                                                                                 123.6
                                                                                                                  123.3          123.6

     121
                                                                                                     119.2
     118                                                                   117.8      120.0

                            114.4
                                                            115.6
     115
                                       111.1

     112


     109


     106                                                                                                          104.3
                                                                                                              Vol/Neg                       104.5
                                                                                                                               103.8                     104.5
                                                                                                    102.2
     103                                                                                                                                                             102.9
                                                                                    100.9
                         100.2                                      99.2                                                                                             101.1
                                            99.4     98.3                                                         102.8        102.4         102.6       102.6
     100
                                                                                                    100.8
                         99.6        98.8                              98.8          100.0
      97                                           98.0
           25-Oct-06   26-Oct-06    27-Oct-06       30-Oct-06   31-Oct-06          1-Nov-06   3-Nov-06       6-Nov-06     7-Nov-06     8-Nov-06     9-Nov-06   10-Nov-06


                                                                     Ibovespa                 IGC           Profarma
3Q06 Results Presentation

Weitere ähnliche Inhalte

Was ist angesagt?

Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10Profarma
 
4Q10 Presentation eng
4Q10 Presentation eng4Q10 Presentation eng
4Q10 Presentation engLocaliza
 
omnicom group Q4 2004 Investor Presentation
omnicom group  Q4 2004 Investor Presentationomnicom group  Q4 2004 Investor Presentation
omnicom group Q4 2004 Investor Presentationfinance22
 
ApresentaçãO ConferêNcia Ubs
ApresentaçãO ConferêNcia UbsApresentaçãO ConferêNcia Ubs
ApresentaçãO ConferêNcia UbsTIM RI
 
ApresentaçãO ConferêNcia Citigroup
ApresentaçãO ConferêNcia CitigroupApresentaçãO ConferêNcia Citigroup
ApresentaçãO ConferêNcia CitigroupTIM RI
 
Apresentação 1 t11 eng
Apresentação 1 t11 engApresentação 1 t11 eng
Apresentação 1 t11 engLocaliza
 
2Q10 final
2Q10 final2Q10 final
2Q10 finalLocaliza
 
omnicom group Q2 2004 Investor Presentation
omnicom group  Q2 2004 Investor Presentation omnicom group  Q2 2004 Investor Presentation
omnicom group Q2 2004 Investor Presentation finance22
 
1Q08 Results Presentation
1Q08 Results Presentation1Q08 Results Presentation
1Q08 Results PresentationJBS RI
 
leggett & platt 2006_fin_complete
leggett & platt 2006_fin_completeleggett & platt 2006_fin_complete
leggett & platt 2006_fin_completefinance39
 
Ernings Release 4 Q08
Ernings Release 4 Q08Ernings Release 4 Q08
Ernings Release 4 Q08Profarma
 

Was ist angesagt? (17)

Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
4Q10 Presentation eng
4Q10 Presentation eng4Q10 Presentation eng
4Q10 Presentation eng
 
omnicom group Q4 2004 Investor Presentation
omnicom group  Q4 2004 Investor Presentationomnicom group  Q4 2004 Investor Presentation
omnicom group Q4 2004 Investor Presentation
 
ApresentaçãO ConferêNcia Ubs
ApresentaçãO ConferêNcia UbsApresentaçãO ConferêNcia Ubs
ApresentaçãO ConferêNcia Ubs
 
Apimec 4 q06 results
Apimec   4 q06 resultsApimec   4 q06 results
Apimec 4 q06 results
 
ApresentaçãO ConferêNcia Citigroup
ApresentaçãO ConferêNcia CitigroupApresentaçãO ConferêNcia Citigroup
ApresentaçãO ConferêNcia Citigroup
 
Apresentação 1 t11 eng
Apresentação 1 t11 engApresentação 1 t11 eng
Apresentação 1 t11 eng
 
4 q08
4 q084 q08
4 q08
 
2Q10 final
2Q10 final2Q10 final
2Q10 final
 
Apimec – 4 q07 results
Apimec – 4 q07 resultsApimec – 4 q07 results
Apimec – 4 q07 results
 
Piaggio Group - First Quarter 2011 Financial Results
Piaggio Group - First Quarter 2011 Financial ResultsPiaggio Group - First Quarter 2011 Financial Results
Piaggio Group - First Quarter 2011 Financial Results
 
omnicom group Q2 2004 Investor Presentation
omnicom group  Q2 2004 Investor Presentation omnicom group  Q2 2004 Investor Presentation
omnicom group Q2 2004 Investor Presentation
 
Investors' meeting 3 q06 results
Investors' meeting   3 q06 resultsInvestors' meeting   3 q06 results
Investors' meeting 3 q06 results
 
1Q08 Results Presentation
1Q08 Results Presentation1Q08 Results Presentation
1Q08 Results Presentation
 
leggett & platt 2006_fin_complete
leggett & platt 2006_fin_completeleggett & platt 2006_fin_complete
leggett & platt 2006_fin_complete
 
Apimec – 3 q07 results
Apimec – 3 q07 resultsApimec – 3 q07 results
Apimec – 3 q07 results
 
Ernings Release 4 Q08
Ernings Release 4 Q08Ernings Release 4 Q08
Ernings Release 4 Q08
 

Andere mochten auch

Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationProfarma
 
Earnings Release 4Q06 Presentation
Earnings Release 4Q06 PresentationEarnings Release 4Q06 Presentation
Earnings Release 4Q06 PresentationProfarma
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07Profarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationProfarma
 
Earnings Release 1 Q09
Earnings Release 1 Q09Earnings Release 1 Q09
Earnings Release 1 Q09Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12Profarma
 

Andere mochten auch (6)

Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
 
Earnings Release 4Q06 Presentation
Earnings Release 4Q06 PresentationEarnings Release 4Q06 Presentation
Earnings Release 4Q06 Presentation
 
Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
Earnings Release 1 Q09
Earnings Release 1 Q09Earnings Release 1 Q09
Earnings Release 1 Q09
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 

Ähnlich wie 3Q06 Results Presentation

Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationProfarma
 
2007 - 7th Analysts And Investors Meeting Results & Performance
2007 - 7th Analysts And Investors Meeting   Results & Performance2007 - 7th Analysts And Investors Meeting   Results & Performance
2007 - 7th Analysts And Investors Meeting Results & PerformanceEmbraer RI
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma
 
Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Tempo
 
HMS Group 9 months 2011 results presentation
HMS Group 9 months 2011 results presentationHMS Group 9 months 2011 results presentation
HMS Group 9 months 2011 results presentationHMS Group
 
4 q12 arezzo_apresentacao_call eng
4 q12 arezzo_apresentacao_call eng4 q12 arezzo_apresentacao_call eng
4 q12 arezzo_apresentacao_call engArezzori
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Engprofarma1
 
VIVO - Apresentation of 2nd Quarter 2009 Results
VIVO - Apresentation of 2nd Quarter 2009 ResultsVIVO - Apresentation of 2nd Quarter 2009 Results
VIVO - Apresentation of 2nd Quarter 2009 ResultsVIVO - Investor Relations
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08Profarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationProfarma
 
Press Release 3 Q03 Tele Celular Sul En
Press Release 3 Q03   Tele Celular Sul EnPress Release 3 Q03   Tele Celular Sul En
Press Release 3 Q03 Tele Celular Sul EnTIM RI
 
Press Release 4 Q03 Tele Celular Sul En
Press Release 4 Q03   Tele Celular Sul EnPress Release 4 Q03   Tele Celular Sul En
Press Release 4 Q03 Tele Celular Sul EnTIM RI
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationProfarma
 
WEG Q4 2012 Conference Call
WEG Q4 2012 Conference CallWEG Q4 2012 Conference Call
WEG Q4 2012 Conference CallWEG
 

Ähnlich wie 3Q06 Results Presentation (20)

Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
Apimec 3 q05 results
Apimec   3 q05 resultsApimec   3 q05 results
Apimec 3 q05 results
 
2007 - 7th Analysts And Investors Meeting Results & Performance
2007 - 7th Analysts And Investors Meeting   Results & Performance2007 - 7th Analysts And Investors Meeting   Results & Performance
2007 - 7th Analysts And Investors Meeting Results & Performance
 
Presentation 4Q09
Presentation 4Q09Presentation 4Q09
Presentation 4Q09
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 
Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Conference Call Presentation 4Q09
Conference Call Presentation 4Q09
 
HMS Group 9 months 2011 results presentation
HMS Group 9 months 2011 results presentationHMS Group 9 months 2011 results presentation
HMS Group 9 months 2011 results presentation
 
4 q12 arezzo_apresentacao_call eng
4 q12 arezzo_apresentacao_call eng4 q12 arezzo_apresentacao_call eng
4 q12 arezzo_apresentacao_call eng
 
Presentation 2Q12
Presentation 2Q12Presentation 2Q12
Presentation 2Q12
 
Presentation 1Q12
Presentation 1Q12Presentation 1Q12
Presentation 1Q12
 
Apimec 2 q05 results
Apimec   2 q05 resultsApimec   2 q05 results
Apimec 2 q05 results
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
 
VIVO - Apresentation of 2nd Quarter 2009 Results
VIVO - Apresentation of 2nd Quarter 2009 ResultsVIVO - Apresentation of 2nd Quarter 2009 Results
VIVO - Apresentation of 2nd Quarter 2009 Results
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
Presentation 3Q12
Presentation 3Q12Presentation 3Q12
Presentation 3Q12
 
Press Release 3 Q03 Tele Celular Sul En
Press Release 3 Q03   Tele Celular Sul EnPress Release 3 Q03   Tele Celular Sul En
Press Release 3 Q03 Tele Celular Sul En
 
Press Release 4 Q03 Tele Celular Sul En
Press Release 4 Q03   Tele Celular Sul EnPress Release 4 Q03   Tele Celular Sul En
Press Release 4 Q03 Tele Celular Sul En
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 Presentation
 
WEG Q4 2012 Conference Call
WEG Q4 2012 Conference CallWEG Q4 2012 Conference Call
WEG Q4 2012 Conference Call
 

Mehr von Profarma

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17Profarma
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17Profarma
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17Profarma
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17Profarma
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17Profarma
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17Profarma
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 PresentationProfarma
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16Profarma
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16Profarma
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16Profarma
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vfProfarma
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejoProfarma
 

Mehr von Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 

3Q06 Results Presentation

  • 1.
  • 2. Conference Call – 3Q06 Results
  • 3.
  • 4. Profarma’s Overview Pharmaceutical Manufacturers Drug Retailers BA GO DF MG ES S RJ PRP SC • 8 Distribution Centers Distribution Centers • > 9,100 Orders Daily • Additional Value Added Services # 120 manufacturers # 23,800 served by Profarma Points-of-Sale Supplied by Profarma Profarma is the fastest growing wholesale distributor of pharmaceutical and personal care products in Brazil
  • 5. Investiment thesis Positive Sector Dynamics Strong Multiple Financial Growth Performance Opportunities Experienced Management Key Player Team Proven Track Record
  • 6. Highlights – 3Q05 vs. 3Q06 - Profarma’s IPO inaugurates company’s new moment - Trade of 17.8 million common shares at R$ 22.50 - Gross funding of R$ 401.0 million - Primary Offer of R$ 310.5 million - 3Q06 Gross Revenues of R$529 million, 16.4% growth over 3Q05 - Net Income totaled R$ 4.2 million, 20.8% more than in the 3Q05. - Adjusted EBITDA reached R$ 19.1 million, 11.4% up year-on-year.
  • 7. Gross Revenues Growth R$ Million 12.9% 16.4% 25.1% 1,439 529 1,725 1,274 125 455 47 1,443 131 97 253 35 90 101 307 1,102 229 76 80 31 252 103 59 60 75 28 185 34 1,184 873 985 361 1,030 312 823 2003 2004 2005 9M2005 9M2006 3Q05 3Q06
  • 8. Net Income R$ Million 33.6% 70.5% 12.0% 20.8% 10.6 5.9 8.9 8.0 4.2 3.5 9M2005 9M2006 3Q05 3Q06 Net Income Net Income, excluding expenses related to the IPO
  • 9. Adjusted EBITDA Adjusted EBITDA (R$ Million) 31.4% 13.8% 11.4% 61.6 35.7 47.1 42.8 48.7 17.1 19.1 2003 2004 2005 9M2005 9M2006 3Q05 3Q06 % of Net Revenues 3.6% 3.7% 4.1% 4.3% 4.1% 3.8% 3.8% 2003 2004 2005 9M2005 9M2006 3Q05 3Q06
  • 10. % of Net Revenues Operating Expenses General & Administratives 2.46% 2.23% 2.14% 2.16% 1.94% 2.14% 2.34% 2.02% 9M2005 9M2006 3Q05 3Q06 Comercial & Marketing General and Administratives 2.34% 2.22% 2.21% 2.24% 2.51% 2.83% 2.34% 2.50% Logistics & Distribution 2.93% 2.44% 2.49% 2.40% 2.92% 2.71% 2.88% 9M2005 9M2006 3Q05 3Q06 2.44% Comercial and Marketing Logistics and Distribution Operating Expenses 7.43% 6.45% 7.11% 7.56% 6.27% 7.01% 6.38% 6.27% 9M2005 9M2006 3Q05 3Q06 2003 2004 2005 9M2006 Operating Expenses
  • 11. Market Follow-up (from October 25 through November 10) 127 126.7 126.2 124 123.6 123.3 123.6 121 119.2 118 117.8 120.0 114.4 115.6 115 111.1 112 109 106 104.3 Vol/Neg 104.5 103.8 104.5 102.2 103 102.9 100.9 100.2 99.2 101.1 99.4 98.3 102.8 102.4 102.6 102.6 100 100.8 99.6 98.8 98.8 100.0 97 98.0 25-Oct-06 26-Oct-06 27-Oct-06 30-Oct-06 31-Oct-06 1-Nov-06 3-Nov-06 6-Nov-06 7-Nov-06 8-Nov-06 9-Nov-06 10-Nov-06 Ibovespa IGC Profarma